Original Article

Effect of Metformin Monotherapy and Combination Therapy with Glimepiride on Lipid Profile in Drug Naive Type-2 Diabetes Patients: A Prospective Observational Study


Background: Dyslipidemia is an important risk factor for development of macrovascular disease. Altered lipid metabolism and abnormality in serum lipid profile results atherogenic dyslipidemia this can worsen the prognosis of diabetic patients and increases risk of cardiovascular disease and stroke.  This study aims to evaluate the effect of metformin monotherapy and combination therapy with glimepiride on lipid profile of drug naive type-2 diabetes patients after 10-12 weeks of treatment. Methods: In this study, prescriptions of 120 OPD (Outpatient department) patients of drug naive type-2 diabetes were collected. The detailed observation of: demographic, drug details and investigations done were noted in a specially designed preform. The data was analyzed statistically and results were expressed as numbers and percentage. Results: The total of 120 patients prescriptions was analyzed. Among these male was 62.5% and female were 37.5%, most common affected age group was between 31-50 years with mean age of 43.82 yrs. Metformin was most commonly prescribed drug 42% followed by its combination with glimepiride 58%. Average blood glucose level prior therapy was 193.4mg/dl and post therapy it was 135.2mg/dl. After 10-12 weeks of metformin monotherapy and combination therapy with glimepiride LDL was significantly reduced from 92.3mg/dl to 83.2mg/dl, TG was reduced from 145.5mg/dl to 132 mg/dl and HDL increased from 29.1 mg/dl to 32.9 mg/dl. Conclusion: Metformin monotherapy and combination therapy with glimepiride appreciably improved dyslipidemia in drug naive type-2 diabetes patients.

1. Rosenblit PD. Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? Cardiovasc Diabetol. 2016;15:95.
2. World Health Organisation, Global report on Diabetes. Geneva, 2016. Accessed 30 August 2016.
3. IDF Diabetes Atlas Tenth Edition https://diabetesatlas.org/
4. Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta. 2004;346:161-170.
5. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:1-15.
6. Lin SH, Cheng PC, Tu ST, Hsu SR, Cheng YC, Liu YH. Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type diabetes mellitus: a cohort study. Peer J. 2018;6:1-10.
7. Folli F, Corradi D, Fanti P, et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011;7(5):313–324.
8. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1):24–38.
9. Shashikala E, Motgi S, Rao RBNV, Sattar MA Study of lipid lowering effects of oral antidiabetic drugs in type 2 diabetes mellitus patients. Int J Basic Clin Pharmacol. 2018;7:126–32.
10. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011 2;14(5):575-85.
11. Xu DY, Zhao SP, Huang QX, et al. Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010; 88(1):71-5.
12. Flort J, Lipska K. Metformin in 2019. JAMA 2019; 321:1926-27
13. Das A, Datta S, Chakrabarty S, et al. An open label prospective observational study of effects of metformin versus metformin plus glimepiride on plasma lipid profile in type II diabetes-mellitus patients in a tertiary care teaching hospital in kolkata. JMSCR. 2018; 6(7):874-878.
14. Buse JB, Tan MH, Prince MJ, Erickson PP. The effect of oral anti-hyperglycaemic medications on serum lipid profile in patients with type 2 diabetes. Diabetes,Obesity and Metabolism. 2004; 6(4):133-156.
15. Lim S, Sohn M, Florez JC, Nauck MA, Ahn J. Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. Nutrients. 2023;15:248.
16. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009;58(2):143-8.
IssueVol 11, No 1 (Winter 2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v11i1.12633
Metformin; Glimepiride; Lipid

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Pareek A, Bhushan A, B S. Effect of Metformin Monotherapy and Combination Therapy with Glimepiride on Lipid Profile in Drug Naive Type-2 Diabetes Patients: A Prospective Observational Study. J Pharm Care. 2023;11(1):2-5.